← Research ProtocolsSS31 / Elamipretide
STUDIED EXPOSURE MAP / 2018
SS31 / Elamipretide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE I–IINEUROLOGYSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
0.01 mg/kg/h
IV infusion · 2 hours
0.1 mg/kg/h
IV infusion · 2 hours
0.25 mg/kg/h
IV infusion · 2 hours
40 mg/day
SC · 4 weeks in MMPOWER-2 crossover · source ↗
Context: A later crossover trial used 40 mg/day SC for 4 weeks. Later phase-3 evidence did not show benefit on its primary functional/fatigue endpoints; exposure alone is not evidence of efficacy.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / NEUROLOGY
Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2018
01 / DESIGNPhase I/II · multicenter · randomized · double-blind · placebo-controlled · dose escalation
02 / POPULATION / MODEL36 adults with genetically confirmed primary mitochondrial myopathy
03 / ROUTEIntravenous infusion
04 / TIMEFRAMEShort dose-escalation study
05 / PRIMARY QUESTIONSafety and 6-minute walk performance
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Mitochondrial-targeting peptide research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.